Chemical Structure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 01)
Plavix
Product Images NDC 67046-604
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 67046-604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 02)
The text describes a chart that shows the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for patients who were given either a placebo with aspirin or Plavix with aspirin over a 12-month follow-up period. The chart shows a significant difference between the two treatments, with Plavix having a lower cumulative event rate. Other standard therapies were also used.*
Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 03)
This appears to be a table of data showing different characteristics of a study group that took either Plavix or placebo. The characteristics include demographic information such as age, gender, and race as well as medical history such as previous heart attacks or strokes and concomitant medications or therapies. There is also mention of hazard ratios with corresponding confidence intervals.*
Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 04)
The text seems to be a comparison of the number of deaths before the first discharge in a placebo group versus a group that received Clopidogrel. The Clopidogrel group had a 7% proportional risk reduction (p=0.03) in deaths compared to the placebo group. The data is plotted over a span of up to 28 days since randomization.*
Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 05)
This text describes the results of a study comparing the effectiveness of a placebo versus the drug Tiopldogrel in reducing the risk of discharge for patients over a 28-day period. The results indicate that the proportion of patients with an event of discharge was 10.1% in the placebo group and 9.2% in the Tiopldogrel group, which represents a 9% proportional risk reduction with the drug (p=0.002). The data is presented graphically with the number of days since randomization.*
Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 06)
This appears to be a statistical analysis report of a clinical trial investigating the effectiveness of Clopidogrel Placebo in treating a medical condition. The report presents data on various subgroups of the trial population, including sex, age, blood pressure, and heart rate, as well as whether or not they were administered a fibrinolytic agent. The report also includes information on the Metoprolol allocation, with a reduction of 1% and a total percentage of 53%.*
Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 07)
This is a table of results from a study that compared the use of Clopidogrel versus Placebo in patients with Killip class I and a previous myocardial infarction. The outcome measures include infarct location and global heterogeneity test. The results show that Clopidogrel was statistically significantly better than Placebo in reducing the proportional reduction of events (p=0.002) at a 95% confidence interval.*
Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 08)
This text presents a graph showing the cumulative event rate in percentage for Faial or Non-Faial vascular events over a period of 36 months of follow-up. The graph compares the effects of two medications, Aspirin and Plavix.*
Blister Of 30 Tablets (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 09)
available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
